PDCD1 and hepatocellular carcinoma: Given the clinical observation that NaHCO3 enhanced the antitumor activity of transarterial chemoembolization in patients with HCC (52), we sought to determine whether systemic buffering would enhance the effect of the anti-PD1 antibody using an aggressive MYC–driven HCC mouse model (18).